Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01991470 · ClinicalTrials.gov registry record · NA
CEP249 Pediatric Accuracy Study
A NA study, sponsored by Medtronic MiniMed.
- Completed
- Registry status
- NA
- Development phase
- 186
- Enrollment target
NCT01991470: Completed NA study, sponsored by Medtronic MiniMed.
NCT01991470 is a NA study that has completed, run by Medtronic MiniMed. The registered enrollment target is 186 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01991470, a NA study, has completed, sponsored by Medtronic MiniMed.
- COMPLETED
- Registry status
- NA
- Development phase
- 186 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the Enlite Sensor™ and Enlite 3 Sensor performance in pediatric patients with insulin requiring diabetes at the beginning, middle and end of sensor wear.
Primary Outcome
Enlite Sensor accuracy relative to the YSI (Yellow Spring Instruments) reference. Each subject wore two 530G pumps. The results for the lower serial number pump worn by each subject were arbitrarily selected and pooled across subjects for the primary dataset. MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) \* 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple testing days were pooled together for re
Interventions
- DEVICE Enlite sensors
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-12 |
| Phase | NA |
What the finished NCT01991470 record still lists
NCT01991470 is an interventional study that assigns participants to a tested intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which Enlite sensors is the first listed.
NCT01991470 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01991470 about?
NCT01991470 is a clinical study titled "CEP249 Pediatric Accuracy Study". The purpose of this study is to evaluate the Enlite Sensor™ and Enlite 3 Sensor performance in pediatric patients with insulin requiring diabetes at the beginning, middle and end of sensor wear.
What is the current status of trial NCT01991470?
This trial is currently completed. It is a NA study. The enrollment target is 186 participants. The study started on 2015-03. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01991470?
The interventions under investigation include: Enlite sensors (DEVICE).
Who is sponsoring clinical trial NCT01991470?
This trial is sponsored by Medtronic MiniMed, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01991470's enrollment target sits among peer trials
186 579th of 2000 higher than 1,421 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia